EFS-Web Receipt date: 12/20/2005

Rec'd PCT/PTO 2 0 DEC 2005

105347771 (640): 1626

PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO Application Number 10/534,777 Filing Date 13 May 2005 INFORMATION DISCLOSURE First Named Inventor DE GROOT STATEMENT BY APPLICANT Art Unit 1614 (Use as many sheets as necessary) **Examiner Name** Unknown Attorney Docket Number 0807840.0103 Sheet 1

U. S. PATENT DOCUMENTS Examiner Cite Document Number Publication Date Name of Patentee or Pages, Colin								
Initials*	Cite No. ¹	Number-Kind Code ^{2 (# known)}	MM-DD-YYYY	Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
		^{US-} 5,965,566	10-12-1999	Greenwald et. al.				
		US-						
		US-						
		US-						
		US-						
•		US-						
		US-						
		US-	_					
		US-						
	1	US-						
	<u> </u>	US-						
		US-						
	<u> </u>	US-						
	 	US-						
	 	US-						
		US-	1					
		US-						
		US-						
	 	US-						

		FORE	IGN PATENT DOCL	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T ⁶
		EP 0 642 799	03-15-1995	Behringwerke AG et al.		
		EP 0 647 450	04-12-1995	Behringwerke AG		
		EP 0 648 503	04-19-1995	Behringwerke AG et al.		
		EP 0 665 020	08-02-1995	Squibb Bristol Myers Co.		
		EP 0 693 485	01-24-1996	Tanabe Seiyaku Co.		
		WO 98/13059	04-02-1998	Squibb Bristol Myers Co.		

Examiner	 Date	•
Signature	Considered	
U.g. attac		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁸Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Sheet 2

PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

0807840.0103

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO Application Number 10/534,777 Filing Date 13 May 2005 INFORMATION DISCLOSURE First Named Inventor **DE GROOT** STATEMENT BY APPLICANT Art Unit 1614 (Use as many sheets as necessary) **Examiner Name** Unknown

Attorney Docket Number

			U. S. PATENT D			
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Wher Relevant Passages or Relevar Figures Appear	
	ــــــ	Number-Kind Code ^{2 (# known)}			rigules Appeal	
		US-			·	
		US-				
		US-				
		US-				
		US-				
		US-				
·· · · · · · · · · · · · · · · · · · ·		US-				
		US-				
		US-				
		US-				
		US-				
-		US-				
		US-				
		US-	1 1.			
		US-		· · · · · · · · · · · · · · · · · · ·		
	1	US-				
		US-				
		US-				
	 	US-				

Examiner	Cite	FORE Foreign Patent Document	IGN PATENT DOCU	Name of Patentee or	Pages, Columns, Lines,	Τ
Initials*	No.1	Toleign Faterit Document	Date	Applicant of Cited Document	Where Relevant Passages	l
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	Τ°
		WO 98/19705	05-14-1998	Squibb Bristol Myers Co.		
		WO 00/34231	06-15-2000	Jones, D.S.; Jolla Pharma		
		WO 02/26220	04-04-2002	Univ. North Carolina		
		EP 1 243 276	09-25-2002	Beusker et al.		
<u> </u>						
-						

Examiner		- -	Date	
Signature		1	Considered	
Oig.icta.o		;	• • • • • • • • • • • • • • • • • • • •	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. *Applicant is to place a check mark here if English language Translation is attached.** Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	ite for form 1449/PTO			Complete if Known		
				Application Number	10/534,777	
	ORMATION			Filing Date	13 May 2005	
STATEMENT BY APPLICANT				First Named Inventor	DE GROOT	
	(Use as many she	ate se na	ocessary)	Art Unit	1614	
	(Use as many site	013 23 77	· .	Examiner Name	Unknown	
Sheet	3	of	3	Attorney Docket Number	0807840.0103	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		DUBOWCHIK G.M. et al, "Cathepsin B-Sensitive dipeptide prodrugs 1", Bioorganic & Medicinal Chemistry Letters, 1 Dec. 1998, 3341-3346, vol. 8, no. 23, Oxford GB	
		DUBOWCHIK G.M. et al, "Cathepsin B-Sensitive dipeptide prodrugs 2", Bioorganic & Medicinal Chemistry Letters, 1 Dec. 1998, 3347-3352, vol. 8, no. 23, Oxford GB	
		DE GROOT F. et al., "Synthesis and Biological Evaluation", Journal of Medicinal Chemistry, American Chemical Society, 1999, 5277-5283, vol. 42 no. 25, Washington US	•
· ·		APPENDINO G. et al., "Synthesis of Paclitaxel", Tetrahedron, 21 May 1999, 6567-6576, vol. 55 no. 21, Elsevier Science Publishers, Amsterdam NL	
		KAR, A. et al., "Synthesis and evaluation of daunorubicin", Bioorganic & Medicinal Chemistry Letters, Feb. 2000, 261-264, vol. 10, no. 3, Oxford GB	
		DE GROOT F. et al., "Synthesis and Biological Evaluation of 2", Journal of Medicinal Chemistry, American Chemical Society, 2000, 3093-3102, vol. 43, Washington US	
		DE GROOT F. et al., "Elongated Multiple Electronic", Journal of Organic Chemistry, 2001, 8815-8830, vol. 66, Easton US	
		DE GROOT F. et al., "Design, Synthesis, and Initial", Proceedings of the Annual Meeting of the American Association for Cancer Research", March 2002, 144, vol. 43, NY US	
		DE GROOT F. et al., "In Vivo Efficacy", Proceedings of the Annual Meeting of the American Association for Cancer Research", March 2002, 415, vol. 43, NY US	

Examiner	/ Joseph Kospek/	Date	07/02/2008
Signature	/Joseph Kosack/	Considered	01/02/2000

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.